▎ 摘　　要

NOVELTY - Transdermal (P1) patch (10) comprises at least one permeation enhancement layers. USE - The patch is useful for: administering naloxone to a subject; transdermally administering a therapeutic compound to a subject, where the therapeutic compound is a useful for treating at least one of overdose, migraine, anaphylaxis, epilepsy, allergy, anxiety, asthma and chronic obstructive pulmonary disease treatments, nausea, vomiting, cancer, diabetes, endocrine disorders, genetic disorders, hormonal disruptions, menopause, arrhythmias, bacterial infections, viral infections, skin cancer, ocular disorders, depression, psychiatric disorders, HIV, AIDS, seizure disorders, and blood pressure changes, and treating psoriasis, atopic dermatitis or eczema (all claimed); and delivering a compound, composition or other substance to a subject, person and/or patient. Test details are described but no results given. ADVANTAGE - The patch: provides a flexible transdermal platform for the administration of a therapeutic compound over a prescribed time course, i.e. rapid onset or prolonged exposure; produces a combined additive or synergistic effect; reduces or eliminates lag time in delivery, and ensures sustained delivery that eliminates the need to re-dose; delivers naloxone dose sufficient to mitigate opioid overdose, while rapidly producing heat at the skin surface without damaging the tissue; has absorption times of ≤ 5 minutes via the use of dissolving microneedles and/or an augmentation layer that can expand the use of transdermal dosage forms to acute medical needs and provide a highly useful in-field solution; and is able to be administered quickly. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: a transdermal (P2) patch for administration of naloxone to a subject, comprising (a) a dissolving microneedle layer (12), (b) an active layer (14), and (c) an augmentation layer (16); transdermally administering a therapeutic compound to a subject, comprising applying a transdermal patch to skin of the subject, where the transdermal patch comprises at least one of a microneedle layer, and the components (b)-(c) as per se, and removing a liner, so that subject skin permeability is enhanced; and a transdermal (P3) patch for administration of a therapeutic compound to a subject, comprising a microneedle layer comprising microneedles comprising the therapeutic compound, and an augmentation layer configured to generate local heat on skin of the subject. DESCRIPTION OF DRAWING(S) - The figure shows a perspective view of a patch. 10Patch 12Dissolving microneedle layer 14Active layer 16Augmentation layer